Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulopenem PK and Safety in Adolescents
NCT04700787Phase 1Withdrawn
- Sponsor
- Iterum Therapeutics plc
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sulopenem in urinary tract infection (UTI), acute pyelonephritis and Intra-abdominal infection (IAI), sponsored by Iterum Therapeutics plc. Primary endpoint: Maximum plasma concentration. Planned start Apr 2021; status: withdrawn.
02
Drugs
sulopenem
03
Conditions
urinary tract infection (UTI)acute pyelonephritisIntra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT04700787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700787.